A detailed history of Cedrus LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Cedrus LLC holds 1,970 shares of ABBV stock, worth $381,234. This represents 0.17% of its overall portfolio holdings.

Number of Shares
1,970
Previous 1,957 0.66%
Holding current value
$381,234
Previous $356 Million 5.18%
% of portfolio
0.17%
Previous 0.19%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$154.79 - $180.76 $2,012 - $2,349
13 Added 0.66%
1,970 $338 Million
Q1 2024

Apr 15, 2024

SELL
$159.82 - $182.1 $65,206 - $74,296
-408 Reduced 17.25%
1,957 $356 Million
Q4 2023

Jan 26, 2024

SELL
$137.6 - $154.97 $44,857 - $50,520
-326 Reduced 12.11%
2,365 $367 Million
Q3 2023

Jan 24, 2024

BUY
$133.59 - $154.65 $31,527 - $36,497
236 Added 9.61%
2,691 $401 Million
Q2 2023

Jan 24, 2024

BUY
$132.51 - $164.9 $3,312 - $4,122
25 Added 1.03%
2,455 $331 Million
Q1 2023

Jan 24, 2024

BUY
$144.61 - $166.54 $351,402 - $404,692
2,430 New
2,430 $387 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $342B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Cedrus LLC Portfolio

Follow Cedrus LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cedrus LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cedrus LLC with notifications on news.